Literature DB >> 16182736

Predictive factors of outcome after liver transplantation in patients with cirrhosis and hepatocellular carcinoma.

M Merli1, G Nicolini, F Gentili, G Novelli, M Iappelli, G Casciaro, U Di Tondo, I Pecorella, A Marasco, A Onetti Muda, F Nudo, G Mennini, S Ginanni Corradini, O Riggio, P Berloco, A F Attili, M Rossi.   

Abstract

Studies to define the optimal upper limits of tumor size and number as predictors of outcome after orthotopic liver transplantation (OLT) have yielded conflicting results. We analyzed 72 patients with cirrhosis and hepatocellular carcinoma (HCC) who underwent OLT over a 12-year period in a single center. Predictive factors for survival and tumor recurrence, according to the Milan criteria, were also examined. Our cohort included 60 men and 12 women of mean age 54 +/- 8 years and mean follow-up of 40 +/- 39 months. Origin of cirrhosis was postviral in 70% and Child class B or C in two thirds of patients. HCC was multifocal in 61%; about one fifth of patients had micro- or macrovascular involvement or positive nodes upon histologic examination. The cumulative size of the lesions was <3 cm in 17 patients; >3 to < or =5 cm in 28 patients; >5 to < or =8 cm in 14 patients; and >8 cm in 13 patients. According to the number and size of tumor nodules, 49 patients met the Milan criteria. During follow-up 25 patients died, 13 due to tumor recurrence. The 1- and 2-year survivals were 90% and 85% for patients who met the Milan criteria versus 57% and 51% for patients exceeding those limits (P = .006). A cumulative tumor size >8 cm was predictive of survival and tumor recurrence upon multivariate analysis. The adoption of Milan criteria for selection of cirrhotic patients has improved survival and reduced the rate of tumor recurrence. The evaluation of cumulative tumor size might further improve patient selection.

Entities:  

Mesh:

Year:  2005        PMID: 16182736     DOI: 10.1016/j.transproceed.2005.06.031

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  7 in total

Review 1.  Advances in predicting the prognosis of hepatocellular carcinoma recipients after liver transplantation.

Authors:  Li-Ying Wang; Shu-Sen Zheng
Journal:  J Zhejiang Univ Sci B       Date:  2018-07       Impact factor: 3.066

2.  Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.

Authors:  John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

3.  The value of serum alpha-fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma.

Authors:  Xiao Xu; Qing-Hong Ke; Zhe-Xin Shao; Jian Wu; Jun Chen; Lin Zhou; Shu-Sen Zheng
Journal:  Dig Dis Sci       Date:  2008-06-18       Impact factor: 3.199

4.  Late recurrence of hepatocellular carcinoma after liver transplantation.

Authors:  Kenneth S H Chok; See Ching Chan; Tan To Cheung; Albert C Y Chan; Sheung Tat Fan; Chung Mau Lo
Journal:  World J Surg       Date:  2011-09       Impact factor: 3.352

Review 5.  Current staging of hepatocellular carcinoma: imaging implications.

Authors:  P Bhosale; J Szklaruk; P M Silverman
Journal:  Cancer Imaging       Date:  2006-07-04       Impact factor: 3.909

6.  Simple Risk Score for Prediction of Early Recurrence of Hepatocellular Carcinoma within the Milan Criteria after Orthotopic Liver Transplantation.

Authors:  Jiliang Feng; Jushan Wu; Ruidong Zhu; Dezhao Feng; Lu Yu; Yan Zhang; Dayu Bu; Chenlei Li; Yuyan Zhou; Lianghao Si; Yuhan Liu; Ziwei Liang; Jianing Xu; Tianjun Wu
Journal:  Sci Rep       Date:  2017-03-09       Impact factor: 4.379

7.  Clinicopathologic features of hepatic neoplasms in explanted livers: a single institution experience.

Authors:  Walid Mourad; Hatem Khalaf; Asma Tulbah; Mohammed Al Omari; Hadeel Al Mana; Mohamed Neimatallah
Journal:  Ann Saudi Med       Date:  2007 Nov-Dec       Impact factor: 1.526

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.